Merck & Co Inc

MRK

Equity

ISIN US58933Y1055 / Valor 10683053

New York Stock Exchange, Inc (2024-09-12)

USD 115.25+0.47%

Merck & Co Inc
UMushroom community rating:

4.00 1 votes No rating yet

NegativeNeutralPositive

About company

Merck & Co Inc, known outside the United States and Canada as Merck KGaA, Darmstadt, Germany, is a global science and technology company with a focus on healthcare, life sciences, and electronics. Founded in 1851, the company has established itself as a pioneer in the science and technology sector, aiming to leverage its expertise to address some of the world's most pressing challenges, including disease, poverty, hunger, and climate change. Merck & Co Inc is committed to driving innovation and growth through its "Mobilize for Growth" strategy, which seeks to unlock the company's full potential and achieve a target of approximately €25 billion in sales by 2025. A significant portion of this growth is expected to come from its three main business sectors: Process Solutions and Life Science Services within the Life Science sector, new Healthcare products, and Semiconductor Solutions within the Electronics sector. The company emphasizes the importance of quality, sustainability, and corporate responsibility in its operations, aiming to create value not only for its customers and patients but also for society at large.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Merck & Co Inc reported a revenue of $16.1 billion for the second quarter of 2024, reflecting a 16% growth compared to the same period last year. This increase was driven by strong sales across various segments, showcasing the company's robust business momentum.

GAAP Earnings Per Share

For the second quarter of 2024, Merck & Co Inc achieved a GAAP earnings per share (EPS) of $2.14. This performance underscores the company's ability to generate substantial earnings, contributing to its overall financial health.

Non-GAAP Earnings Per Share

Merck & Co Inc reported a non-GAAP EPS of $2.28 for the second quarter of 2024. This figure represents a 2% growth compared to the previous year, highlighting the company's consistent financial performance and operational efficiency.

Updated Financial Outlook

Merck & Co Inc has updated its financial outlook for the full year 2024, projecting sales to be in the range of $63.4 billion to $64.4 billion. This revised forecast reflects the company's confidence in its continued growth and market position.

Pipeline and Milestones

During the second quarter of 2024, Merck & Co Inc achieved significant regulatory and clinical milestones, further expanding and diversifying its pipeline. These advancements are crucial for the company's long-term strategy and commitment to addressing unmet medical needs.

Summarized from source with an LLMView Source

Key figures

5.71%1Y

56.9%3Y

44.9%5Y

Performance

20.9%1Y

21.9%3Y

23.6%5Y

Volatility